Reviewer’s report

Title: Composite hemangioendothelioma of the forehead and right eye: A case report

Version: 1 Date: 06 Aug 2017

Reviewer: Gopikrishnan Anjaneyan

Reviewer's report:

Dear author,

It's a good case report highlighting the importance of this newly described entity linking the benign and malignant!..

Appreciate the images too.

Following are my suggestions for fine tuning -

line 63 -may be edited and references added..

According to previous studies, there is an association between the CHE and some tumors (such as vascular tumors) and hemangioma.

lines 83-89 -kindly rearrange - MRI 'examination' and 'findings' has a 'chief complaint' sentence sandwiched in-between.

A soft tissue with a slightly lobulated surface was observed using magnetic resonance imaging (MRI). The chief complaint of the patient was ...... undergoing radiotherapy or chemotherapy. The result of the brain MRI in May 2015 demonstrated a mucosal thickening in the right maxillary sinus

line 115- kindly mention the details of the biopsy taken, type of biopsy, site margins etc.

Five months later, the microscopic examination revealed a malignant vascular neoplasm composed of a…
line 123 kindly edit these 2 line and merge if required (eg ...neoplastic tissue...therefore IHC was performed)

The biopsy examination demonstrated a neoplastic tissue composed of a papillary structure and an alveolar pattern. Therefore, the patient was referred to undergo the immunohistochemistry (IHC) test

line 128 change CHT=CHE

Based on the combination of histopathological findings and IHC results, the patient was diagnosed with CHT;

line 147 - may be edited and references added..

So far, about 40 cases with CHE have been reported in previous studies; these were mainly located at the cutaneous level

156 line- eye examination..

however, the patient's eye exam was normal.

line 170- kindly elaborate

Therefore, the dentition of pure components of CHE is difficult.

line 202 ,212 kindly edit & rearrange

Thalidomide and was first used as an antiemetic, but, sadly, soon linked to phocomelia birth defects.
thalidomide led to reducing in periorbital edema and eliminating the lesion pressure effect the tumor did not regress completely.

line 215 -kindly edit & rearrange

The evidence of the coexistence of variable components of the CHE was suggested in our study,
indicating that the CHE has a distinctive morphology and biology.

figure 2 histopathology image- the magnification can be mentioned in the collage top corner of each box.

also please go through the case presentation part and rearrange the events in a continuous flow of events: the past & present history of presentation and investigations done.

Thanks
regards

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal